Ritter Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2004-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://ritterpharma.com
Evaluation of the Efficacy, Durability, Safety, and Tolerability of RP-G28 in Patients With Lactose Intolerance
- First Posted Date
- 2018-07-24
- Last Posted Date
- 2019-07-08
- Lead Sponsor
- Ritter Pharmaceuticals, Inc.
- Target Recruit Count
- 557
- Registration Number
- NCT03597516
- Locations
- 🇺🇸
Research Site, Bellevue, Washington, United States
🇺🇸Reseaarch Site, Pompano Beach, Florida, United States
🇺🇸Research Facility, Miami, Florida, United States
Effect of a Standard Meal on the Pharmacokinetic Profile of RP-G28 in Healthy Adult Male and Female Subjects
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2018-08-08
- Lead Sponsor
- Ritter Pharmaceuticals, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT03563846
- Locations
- 🇺🇸
Syneos Health, Miami, Florida, United States
Efficacy, Safety, and Tolerability Study of RP-G28 in Subjects With Lactose Intolerance
- First Posted Date
- 2016-02-04
- Last Posted Date
- 2018-04-04
- Lead Sponsor
- Ritter Pharmaceuticals, Inc.
- Target Recruit Count
- 377
- Registration Number
- NCT02673749
- Locations
- 🇺🇸
Covance, Inc., Princeton, New Jersey, United States
Effectiveness, Safety and Tolerability Study of RP-G28 for Symptoms Associated With Lactose Intolerance
Phase 2
Completed
- Conditions
- Lactose Intolerance
- Interventions
- Drug: RP-G28 or placebo
- First Posted Date
- 2010-04-30
- Last Posted Date
- 2011-12-08
- Lead Sponsor
- Ritter Pharmaceuticals, Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT01113619
- Locations
- 🇺🇸
Covance, Inc. - Honolulu, Honolulu, Hawaii, United States
🇺🇸Covance, Inc. - Dallas, Dallas, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath